



CERTIFICATE OF MAILING

WE HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON JUNE 20, 2003

E. A. Meade

Eric A. Meade, REG. NO. 42,876

6-20-03

DATE

Attorney Docket No. BM45323

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ruelle et al.

Group Art Unit: 1645

Serial No.: 09/701,271

Examiner: unknown

Filed: March 11, 2002

For: *Neisseria Meningitidis* Antigenic Polypeptides, Corresponding Polynucleotides and Protective Antibodies

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

JUN 25 2003

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.56**

TECH CENTER 1600/2900

Listed on the included Form PTO-1449 are references cited in the International Search Report (ISR) for PCT/EP99/03603. The ISR and references have already been received by the United States Patent and Trademark Office as indicated in the 371 Acceptance Notice (PCT/EO/903).

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

(1) This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.
- ☒ **before the mailing date of a first Office Action on the merits.**

- ☐ **after** the mailing date of the first Office Action on the merits, but **before** the mailing date of
- a Final Action under 37 CFR 1.113,
 - a Notice of Allowance under 37 CFR 1.311, or
 - an action that otherwise closes prosecution,
- and is accompanied by either:
- ☐ the Statement under 37 CFR 1.97(e) (see "Statement" below), **or**
- ☐ the fee under 37 CFR 1.17(p).
- ☐ **after** the mailing date of
- a Final Action under 37 CFR 1.113,
 - a Notice of Allowance under 37 CFR 1.311, or
 - an action that otherwise closes prosecution,,
- and is accompanied by both:
- the Statement under 37 CFR 1.97(e) (see "Statement" below), **and** the fee under 37 CFR 1.17(p).

(2) **Statement**

- ☐ The **undersigned attorney** hereby states that each item information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement. *(If this box is checked, do not check any further Statement boxes.)*

or

- ☐ The **person signing immediately below** hereby states that no item of information contained in the Supplemental Information Disclosure was cited in any communication from any foreign patent office in any counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Supplemental Information Disclosure Statement.

The person making the statement is:

- ☐ the inventor(s) who sign(s) below:

Signature of the Inventor(s)

Typed or Printed Name of the Inventor(s)

or

- ☐ a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:

Signature of the Person(s)

Typed or Printed Name of the Person

Address of Person Signing

or

- ☐ the undersigned attorney who signs on the basis of the information:
- ☐ supplied by the inventor(s).
 - ☐ supplied by an individual designated in 37 CFR 1.56(c).
 - ☐ in the attorney's file.

Signature of the Attorney (4) Fees

- ☒ **No Fee** is owed by the applicants.
- ☐ **The IDS Fee** of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.

(5) Method of Payment of Fees


- ☐ Attached is a check in the amount of \$_____.
- ☐ Applicants hereby authorize the Commissioner to charge the \$180.00 IDS Fee to Deposit Account No. 50-0258.

(6) **Authorization to Charge Additional Fees**

- ☒ Applicants hereby authorize the Commissioner to charge any additional fees deemed required for consideration of this Paper to Deposit Account No. 50-0258.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,


Eric A. Meade
Registration No. 42,876

DECHERT LLP
A Pennsylvania Limited Liability Partnership
Princeton Pike Corporate Center
PO Box 5218
Princeton, New Jersey 08543-5218
Phone: (609) 620-3248
Fax: (609) 620-3259




Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number	09/701,271
Filing Date	March 11, 2002
First Named Inventor	Ruelle, Jean-Louis
Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	BM45323

RECEIVED
JUN 25 2003
TECH CENTER 1600/2900

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (02-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 09/701,271

Filing Date March 11, 2002

First Named Inventor Ruelle, Jean-Louis

Art Unit 1645

Examiner Name unknown

Attorney Docket Number BM45323

RECEIVED

JUN 25 2003

TECH CENTER 1600/2900

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Accession Number: U40596, 3 February 1996	
		DRAKE S ET AL, The product of the pilQ gene is essential for the biogenesis of type IV pili in Neisseria gonorrhoeae, MOL. MICROBIOL., December 1995, pages 975-986, vol. 18, no. 5	
		Accession Number: AF066056, 18 December 1998	
		TONJUM T ET AL, Structure and function of repetitive sequence elements associated with a highly polymorphic domain of the Neisseria meningitidis PilQ protein, MOL. MICROBIOL., July 1998, pages 111-124, vol. 29, no. 1	
		PETTERSSON A ET AL, Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bacterial and strain specific, INFECT. IMMUN., September 1990, pages 3036-3041, vol. 58, no. 9	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.